ADC Toxin & Linker Screening

The selection of suitable payloads and linker technologies is a critical step in ADC development, influencing conjugation efficiency, drug loading, stability, payload release, and overall developability. Protheragen provides toxin and linker screening services covering payload selection, linker evaluation, linker-payload design and synthesis, analytical assessment, and developability evaluation to support the identification of suitable ADC building blocks for downstream conjugation and process development.

Overview of ADC Toxin & Linker Screening

An ADC combines an antibody with a potent payload through a chemically or enzymatically designed linker. While the antibody provides target recognition, the linker and payload determine important aspects of drug release, intracellular activity, physicochemical behavior, and product stability. Therefore, selecting an appropriate linker-payload combination requires consideration of potency, chemical stability, conjugation compatibility, hydrophobicity, release characteristics, and manufacturability.

Payload selection is not determined by cytotoxic potency alone. Candidate payloads need to provide appropriate biological activity together with sufficient stability, chemical functionality for conjugation, and physicochemical properties compatible with ADC preparation. Highly hydrophobic payloads, for example, can affect ADC aggregation and drug loading, while linker design can be used to improve hydrophilicity and influence the behavior of the resulting conjugate.

Linkers also play an important role in controlling the stability of the ADC in circulation and the release of the active payload at the intended site. Cleavable and non-cleavable linkers can provide different release mechanisms, and linker selection needs to be aligned with the selected payload, conjugation chemistry, and desired product characteristics.

Fig.1 Structure and mechanism of action of ADC. (Tsuchikama, K., et al., 2018)

Our Services

Integrated Screening Strategy

Toxin and linker selection is closely connected with subsequent conjugation and ADC process development. A systematic screening strategy can reduce the risk of advancing a highly potent payload or linker that later presents challenges in conjugation, purification, stability, or manufacturing.

Linker Selection Considerations

The linker serves as more than a chemical connection between the antibody and payload. Its design can influence ADC stability, payload release, hydrophobicity, conjugation behavior, and ultimately therapeutic performance.

Key considerations include:

• Circulation Stability

The linker should maintain sufficient stability during systemic circulation to minimize premature payload release.

• Controlled Payload Release

Cleavable linkers can be designed to respond to specific intracellular or tumor-associated conditions, while non-cleavable linkers rely on intracellular processing of the ADC to release the active drug species.

• Physicochemical Properties

Hydrophilic linker components can help compensate for hydrophobic payloads and may reduce undesirable aggregation or other developability challenges.

• Conjugation Compatibility

The linker must be compatible with the selected conjugation chemistry and antibody format to support efficient and consistent ADC construction.

• Manufacturing Feasibility

Synthetic complexity, purification requirements, stability, and scalability should also be considered when prioritizing linker-payload candidates.

Screening Workflow

Protheragen supports a structured workflow for evaluating linker and payload candidates:

Why Choose Protheragen

• Integrated Linker-Payload Development

Screening is connected with linker-payload synthesis, purification, analytical evaluation, and developability assessment, providing a more complete basis for candidate selection.

• Flexible Candidate Screening

Payload and linker combinations can be evaluated according to the specific antibody, target, conjugation strategy, and development objectives rather than relying on a single predefined combination.

• Chemistry and CMC-Oriented Evaluation

Candidate selection considers not only biological activity but also chemical stability, conjugation compatibility, purification, and manufacturing feasibility.

• Analytical Support Throughout Screening

Analytical evaluation provides supporting data for comparing linker-payload candidates and monitoring synthesis and purification performance.

• Seamless Transition to ADC Development

Selected linker-payload candidates can progress into subsequent conjugation, process development, analytical characterization, and manufacturing activities, helping maintain continuity across the ADC development lifecycle.

The selection of an appropriate payload and linker combination can influence the downstream performance, stability, and manufacturability of an ADC. By integrating candidate screening with linker-payload design, synthesis, analytical evaluation, and developability assessment, Protheragen supports informed candidate selection and provides a foundation for subsequent ADC conjugation and process development. Have a specific ADC payload, linker, or linker-payload combination that requires evaluation? Contact us to discuss your target, antibody, development stage, and project requirements. Our team can help develop a screening and evaluation strategy aligned with your ADC program.